SG52834A1 - 11- (substituted phenyl) - estra-4, 9-diene derivatives - Google Patents

11- (substituted phenyl) - estra-4, 9-diene derivatives

Info

Publication number
SG52834A1
SG52834A1 SG1996010458A SG1996010458A SG52834A1 SG 52834 A1 SG52834 A1 SG 52834A1 SG 1996010458 A SG1996010458 A SG 1996010458A SG 1996010458 A SG1996010458 A SG 1996010458A SG 52834 A1 SG52834 A1 SG 52834A1
Authority
SG
Singapore
Prior art keywords
estra
substituted phenyl
diene derivatives
diene
derivatives
Prior art date
Application number
SG1996010458A
Other languages
English (en)
Inventor
Ronald Gebhard
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8220570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG52834(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of SG52834A1 publication Critical patent/SG52834A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG1996010458A 1995-08-17 1996-08-14 11- (substituted phenyl) - estra-4, 9-diene derivatives SG52834A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95202229 1995-08-17

Publications (1)

Publication Number Publication Date
SG52834A1 true SG52834A1 (en) 1998-09-28

Family

ID=8220570

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996010458A SG52834A1 (en) 1995-08-17 1996-08-14 11- (substituted phenyl) - estra-4, 9-diene derivatives

Country Status (26)

Country Link
US (1) US6011025A (ru)
EP (1) EP0763541B1 (ru)
JP (1) JP3977462B2 (ru)
KR (1) KR100445376B1 (ru)
CN (1) CN1129602C (ru)
AR (1) AR003982A1 (ru)
AT (1) ATE182596T1 (ru)
AU (1) AU711369B2 (ru)
BR (1) BR9603429A (ru)
CA (1) CA2182771C (ru)
CZ (1) CZ287740B6 (ru)
DE (1) DE69603425T2 (ru)
DK (1) DK0763541T3 (ru)
ES (1) ES2137625T3 (ru)
GR (1) GR3031116T3 (ru)
HK (1) HK1002010A1 (ru)
HU (1) HU229023B1 (ru)
IL (1) IL118974A (ru)
NO (1) NO306257B1 (ru)
NZ (1) NZ299181A (ru)
PL (1) PL183468B1 (ru)
RU (1) RU2135514C1 (ru)
SG (1) SG52834A1 (ru)
TR (1) TR199600664A2 (ru)
TW (1) TW464654B (ru)
ZA (1) ZA966555B (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903146A1 (en) * 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
EP1726307A3 (en) * 1997-10-06 2007-04-04 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychosis associated with glucocorticoid related dysfunction
CN1187053C (zh) * 1997-10-06 2005-02-02 利兰·斯坦福青年大学托管委员会 糖皮质素受体拮抗剂用于制造治疗精神病药物的用途
KR20010043630A (ko) 1998-05-15 2001-05-25 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 치매의 치료를 위한 글루코코티코이드 수용체 길항제
EP1212345B1 (en) * 1999-04-06 2003-08-06 Akzo Nobel N.V. Orally active 7-alpha-alkyl androgens
DK1363876T3 (da) * 2001-02-14 2009-11-30 Karobio Ab Glucocorticoidreceptormodulatorer
EP1285927A3 (de) 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
EP1652526B1 (en) * 2001-10-26 2009-01-14 N.V. Organon Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder
AU2002366217A1 (en) * 2001-11-23 2003-06-10 Akzo Nobel N.V. Treatment of major depressive disorder using glucocorticoid receptor antagonists
US8450379B2 (en) * 2002-11-05 2013-05-28 Corcept Therapeutics, Inc. Methods for treating migraine
CA2514966A1 (en) * 2003-02-04 2004-08-19 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of postpartum psychosis
TW200820977A (en) 2006-08-08 2008-05-16 Organon Nv Use of glucocorticoid receptor antagonists for treatment of infectious conditions
WO2012106514A2 (en) * 2011-02-03 2012-08-09 Pop Test Cortisol Llc System and method for diagnosis and treatment
US20120245552A1 (en) * 2011-03-23 2012-09-27 Pop Test Cortisol Llc Combination Therapy
WO2012135274A1 (en) 2011-03-31 2012-10-04 Pop Test Cortisol Llc Prevention of infection
WO2012145258A1 (en) * 2011-04-18 2012-10-26 Pop Test Cortisol Llc Hair loss treatment
US8986677B2 (en) 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
WO2015187289A1 (en) 2014-06-03 2015-12-10 Pop Test Abuse Deterrent Technology Llc Drug device configured for wireless communication
EP3265127B1 (en) * 2015-03-02 2024-02-21 Corcept Therapeutics, Inc. Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor
US10053485B2 (en) 2015-03-23 2018-08-21 Evestra, Inc. Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents
AU2016243625B2 (en) 2015-03-30 2020-09-10 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
EP3400233A4 (en) * 2015-08-03 2020-02-26 Pop Test Oncology LLC PHARMACEUTICAL COMPOSITIONS AND METHODS
US9598459B2 (en) * 2015-08-03 2017-03-21 Pop Test Oncology Llc Pharmaceutical compositions and methods
CA2994422A1 (en) 2015-08-13 2017-02-16 Corcept Therapeutics, Inc. Method for differentially diagnosing acth-dependent cushing's syndrome
US11208432B2 (en) 2015-12-23 2021-12-28 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
AU2016377702B2 (en) * 2015-12-23 2021-03-11 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
ES2861524T3 (es) 2016-01-19 2021-10-06 Corcept Therapeutics Inc Diagnóstico diferencial del Síndrome de Cushing Ectópico
CN111690031B (zh) * 2016-10-07 2021-06-01 欧瑞克制药公司 糖皮质激素受体抑制剂
CA3065555A1 (en) 2017-06-20 2018-12-27 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2522328B1 (fr) * 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
DE3708942A1 (de) * 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3717169A1 (de) * 1987-05-19 1988-12-01 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
ES2124905T3 (es) * 1993-08-04 1999-02-16 Akzo Nobel Nv Esteroides antiglucocorticoides destinados al tratamiento de trastornos de ansiedad.
DE69500542T2 (de) * 1994-05-19 1998-01-02 Akzo Nobel Nv 11,21-Bisphenyl-19-nor-pregnan Derivate

Also Published As

Publication number Publication date
NO963427D0 (no) 1996-08-16
TR199600664A2 (tr) 1997-03-21
ZA966555B (en) 1997-02-19
GR3031116T3 (en) 1999-12-31
CA2182771C (en) 2007-04-24
CZ238696A3 (en) 1997-05-14
EP0763541A1 (en) 1997-03-19
IL118974A (en) 2001-09-13
DE69603425D1 (de) 1999-09-02
ATE182596T1 (de) 1999-08-15
TW464654B (en) 2001-11-21
PL315733A1 (en) 1997-03-03
CZ287740B6 (en) 2001-01-17
ES2137625T3 (es) 1999-12-16
CN1147520A (zh) 1997-04-16
NZ299181A (en) 1997-09-22
JPH09104696A (ja) 1997-04-22
MX9603476A (es) 1997-07-31
EP0763541B1 (en) 1999-07-28
HU9602269D0 (en) 1996-10-28
US6011025A (en) 2000-01-04
KR970010784A (ko) 1997-03-27
NO963427L (no) 1997-02-18
BR9603429A (pt) 1998-05-12
HU229023B1 (en) 2013-07-29
HK1002010A1 (en) 1998-07-24
JP3977462B2 (ja) 2007-09-19
DE69603425T2 (de) 2000-01-20
AU711369B2 (en) 1999-10-14
KR100445376B1 (ko) 2004-11-08
DK0763541T3 (da) 2000-02-28
CA2182771A1 (en) 1997-02-18
AU6211996A (en) 1997-02-20
RU2135514C1 (ru) 1999-08-27
PL183468B1 (pl) 2002-06-28
HUP9602269A2 (en) 1997-04-28
AR003982A1 (es) 1998-09-30
IL118974A0 (en) 1996-10-31
HUP9602269A3 (en) 1997-12-29
NO306257B1 (no) 1999-10-11
CN1129602C (zh) 2003-12-03

Similar Documents

Publication Publication Date Title
GR3031116T3 (en) 11-(Substituted phenyl)-estra-4,9-diene derivatives
ZA961444B (en) Pyrazolylbenzoyl derivatives.
ZA9710573B (en) New substituted pyrazole derivatives.
HK1018216A1 (en) New 19-nor-pregnene derivatives.
HU9700126D0 (en) 2-oxo- and 2-thio-1,2-dihydroquinolinyl-oxazotidinone derivatives
ZA9884B (en) 16-Hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives
ZA961449B (en) Isoxazolylbenzoyl derivatives.
IL134220A0 (en) 6,9-bridged erythromycin derivatives
IL126624A0 (en) 3-descladinose-2, 3-anhydroerythromycin derivatives
IL134996A0 (en) 6,11-bridged erythromycin derivatives
ZA969973B (en) 2-thioxo-imidazolidin-4-one derivatives.
GB9411088D0 (en) Hydroxylamine derivatives
ZA989431B (en) D-homo-9,10-secochloldesta-23-yne-3,25-diol derivatives
ZA966048B (en) Piperazine derivatives.
HU9600871D0 (en) New 2,3-benzodiazepine derivatives
ZA974953B (en) Substituted pyrazolylpyrazole derivatives.
ZA967741B (en) Diarylalkenylamine derivatives.
PL326837A1 (en) 25-hydroxy-16-ene-26, 27-bishomocholecarctiferoles
ZA962821B (en) 4-indolylpiperazinyl derivatives.
ZA967357B (en) Pyrazol-4-ylbenzoyl derivatives.
ZA983902B (en) Erythromycin derivatives.
ZA964034B (en) N-aminopyridone derivatives.
ZA968953B (en) 24-homo-26,27-hexafluoro-cholecalciferols
HUP0302187A3 (en) 11-(substituted phenyl)-estra-4,9-diene derivatives, their production and use as medicament
ZA953005B (en) 5-heterocyclo-1,5-benzodiazepine derivatives